

GLP-1 Receptor Agonists in Polycystic Ovary Syndrome Management

Subjects: Medicine, General & Internal
Contributor: Mojca Jensterle, Rok Herman, Andrej Janež

Polycystic ovary syndrome (PCOS) is the most common metabolic and hormonal disorder in reproduction-aged women. Its pathogenesis involves multiple organ systems and is tightly associated with a higher predisposition and prevalence of abdominal obesity and insulin resistance. Profound weight loss effects in diabetic and non-diabetic patients gave birth to the idea that GLP-1 receptor agonists (GLP-1RAs) could be used in a subgroup of women with PCOS.

Keywords: GLP-1 receptor ; polycystic ovary syndrome ; management

1. The Efficacy of GLP-1 Receptor Agonists in Weight Management in Polycystic Ovary Syndrome

In 2014, the United States Food and Drug Administration (FDA) approved liraglutide as the first GLP-1 receptor agonist (GLP-1RA) that can be used for obesity management in patients without diabetes [1]. In 2021, semaglutide followed with indications in obese patients (BMI above 30 kg/m²) or overweight patients (BMI above 27 kg/m²) with at least one adipose-based chronic diseases (ABCD) [2]. GLP-1RAs alone or combined with metformin have been investigated in several small studies with overweight/obese PCOS women [3]. **Table 1** summarizes the clinical studies that measured the weight-reducing effects of GLP-1RAs in PCOS patients as one of their outcomes.

Additional insight was provided by a network meta-analysis including 23 studies and 951 women, which compared the effectiveness of liraglutide, orlistat, and metformin in promoting weight loss in PCOS women. Liraglutide monotherapy was superior in reducing body weight and waist circumference. Furthermore, its efficacy was the highest at the daily dose of 3 mg [4].

Table 1. Clinical studies that measured the weight loss effects of GLP-1RAs in PCOS.

Population Studied	Study Type	Duration	Study Arms	Weight Loss	Other Remarks	Ref
40 obese nondiabetic women with PCOS who had lost <5% body weight during pretreatment with metformin	Open-label, prospective study	12 weeks	Metformin 1000 mg BID	-1.2 ± 1.4 kg	WC also decreased by 5.5 ± 3.8 cm in the combination arm compared with 3.2 ± 2.9 cm in liraglutide and 1.6 ± 2.9 cm in the metformin arm. The majority of patients who achieved at least 5% of weight reduction were on combination therapy or liraglutide monotherapy.	[5]
			liraglutide 1.2 mg QD s.c.	-3.8 ± 3.7 kg		
			metformin 1000 mg BID and liraglutide 1.2 mg QD s.c	-6.5 ± 2.8 kg		
32 obese women with newly diagnosed PCOS	Open-label, prospective study	12 weeks	Metformin 1000 mg BID	-2.3 kg	Comparable results were found for the reduction of BMI, WC and whole-body fat mass. However, in a subgroup of patients with the combination of extreme obesity and insulin resistance, the patients achieved better results with liraglutide compared to metformin.	[6]
			Liraglutide 1.2 mg QD s.c.	-3.0 kg		

Population Studied	Study Type	Duration	Study Arms	Weight Loss	Other Remarks	Ref
84 overweight/obese women with PCOS	Observational study	a minimum of 4 weeks; a mean duration of treatment was 27.8 weeks	Starting dose was 0.6 mg liraglutide given s.c. QD. If the weight was not reduced, the dose was increased to 1.2 mg and if necessary to 1.8 mg.	-9.0 kg	81.7% of patients achieved beyond 5% weight loss, and 32.9% of patients achieved more than 10% weight loss.	[7]
72 women with PCOS, with a BMI > 25 kg/m ² and/or insulin resistance	Prospective, double-blind, placebo-controlled, randomized clinical trial	26 weeks	Placebo	0.2 kg	Body weight reduction of more than 5% was achieved in 55% and 14% of participants in the liraglutide and placebo groups, respectively. In addition to liver fat content, VAT and SAT were reduced by 18.6% and 10.0%, respectively.	[8]
			liraglutide 1.8 mg QD s.c	-5.2 kg		
44 obese women with PCOS	Open-label, prospective, randomized control trial	12 weeks	Liraglutide 1.2 mg QD s.c.	-3.8 ± 3.5 kg	59.1% of patients in the combination groups vs. 42.9% of patients in the liraglutide-only group achieved beyond 5% weight reduction.	[9]
			metformin 1000 mg BID and liraglutide 1.2 mg QD s.c.	-6.2 ± 2.4 kg		
31 obese patients with PCOS	Retrospective study	6 months	Metformin 500 or 1000 mg daily	-4.9 kg	Liraglutide was superior in the analysis of the number of patients that achieved 5% or 10% weight loss.	[10]
			Liraglutide doses of 1.8 mg and 3.0 mg or semaglutide dosing up to 1 mg	-9.1 kg		
50 overweight/obese PCOS women	Open-label prospective, randomized, clinical trial	12 weeks	Metformin 500 mg TID	-2.1 ± 3.0 kg	WC decreased by 4.63 ± 4.4 cm in combination group compared with 1.72 ± 3.07 cm in the metformin-only group.	[11]
			metformin 500 mg TID, exenatide 2 mg QW	-3.8 ± 2.4 kg		
60 overweight oligoovulatory women with PCOS	Open-label prospective, randomized, clinical trial	24 weeks	Metformin 1000 mg BID	-1.6 ± 0.2 kg	Combination therapy was more efficient compared to to exenatide or metformin in reducing abdominal fat.	[12]
			exenatide 10 mcg BID	-3.2 ± 0.1 kg		
19 obese women with PCOS	Open label, prospective	6 months	metformin 1000 mg BID and exenatide 10 mcg BID	-6.0 ± 0.5 kg	/	[13]
			Liraglutide 1.8 mg QD	-3.0 ± 4.2 kg		
45 obese PCOS women	Open-label, prospective, randomized clinical trial	12 weeks	Metformin 1000 mg BID	-0.2 ± 1.8 kg	Liraglutide also resulted in significant decrease in VAT area and was superior in reducing WC.	[14]
			roflumilast 500 mcg QD	-2.1 ± 2.0 kg		
30 obese PCOS women	Open-label prospective randomized clinical trial	12 weeks	liraglutide 1.2 mg QD	-3.1 ± 3.5 kg	WC reduction in liraglutide arm was greater than in combination.	[15]
			Metformin 1000 mg BID and liraglutide 1.2 mg QD	-3.6 ± 2.5 kg		
			liraglutide 3.0 mg QD	-6.3 ± 3.7 kg		

Population Studied	Study Type	Duration	Study Arms	Weight Loss	Other Remarks	Ref
28 infertile obese PCOS patients	Open-label prospective randomized clinical trial	12 weeks	Metformin 1000 mg BID	-7.0 ± 6.0 kg	Weight reduction beyond 5% was seen in 69.2% of patients in the combination group and 57.1% of patients in the metformin-only group. Significant and similar decreases in WC, VAT area, and volume were noticed between groups.	[16]
176 overweight/obese women with PCOS	Open-label prospective, randomized clinical trial	24 weeks	metformin 1000 mg BID combined with liraglutide 1.2 mg QD	-7.5 ± 3.9 kg		
			Metformin 1000 mg BID	-2.3 ± 0.6 kg	47% of patients achieved beyond 5% weight loss with exenatide therapy in the first 12 weeks, but no subject demonstrated similar weight loss with MET therapy. The decrease in WC was more significant in patients on exenatide than those in patients on metformin. Exenatide therapy resulted in significant decreases in abdominal fat.	[17]
30 overweight/obese anovulatory women with all 3 Rotterdam criteria	Open label, prospective study	16 weeks	exenatide 10 µg BID (first 12 weeks), metformin 1000 mg BID (second 12 weeks)	-4.3 ± 1.3 kg		
			exenatide 5 mcg BD for 4 weeks then 10 mcg BD for 12 weeks	-3.2 kg	There was no effect on WC but there was a reduction in hip circumference.	[18]
32 overweight/obese PCOS patients	Prospective study	12 weeks	the initial dose of exenatide 5 µg BD was increased to 10 µg BD after 1 month	-6.0 kg	After exenatide treatment, the body adipose distribution—related indexes, including body fat content, WC, and hipline circumference, decreased.	[19]
			once-weekly 2 mg exenatide (EQW)	-4.1 kg		
			dapagliflozin 10 mg daily (DAPA)	-1.4 kg		
119 nondiabetic obese women with PCOS	Single-blinded, randomized controlled trial	24 weeks	coadministered EQW/DAPA	-6.0 kg	The combination of exenatide and dapagliflozin resulted in superior weight and total body fat reductions than either therapy individually.	[20]
			DAPA/extended-release (ER) metformin 2000 mg daily (DAPA/MET)	-1.8 kg		
			phentermine 7.5 mg/topiramate extended release 46 mg ER daily	-9.0 kg		
25 obese women with PCOS	Randomized single-blind, pilot study	16 weeks	placebo	-1.9 ± 1.5 kg	Tongue fat tissue and fat proportion significantly reduced after semaglutide vs. placebo and were associated with those in body weight, BMI and WC.	[21]
			semaglutide 1.0 mg	-5.2 ± 4.0 kg		
182 women with PCOS	Randomized controlled trial	12 weeks	metformin 1000 mg BID	-3.6 kg	There was a significant decrease in WC in both treatment groups, and exenatide group was better in changes of WC than metformin group.	[22]
			exenatide 10 µg BID	-5.2 kg		

Legend: WC—waist circumference, VAT—visceral adipose tissue, SAT—subcutaneous adipose tissue.

2. The Additional Metabolic Effects of GLP-1 Receptor Agonists in Polycystic Ovary Syndrome

Beyond its weight loss effect, multiple studies provided additional insight into the metabolic benefits of GLP-1RAs in PCOS. Due to the high prevalence of prediabetes in PCOS, additional insights could be gained from a study in which metformin, exenatide, and their combination were studied to explore their effect on prediabetes remission rate. The remission rate of the combination group (64%) or exenatide group (56%) was significantly higher than that of the metformin group (32%), most likely due to the improvement of postprandial insulin secretion. It is also essential to notice that the effects of exenatide therapy persisted after 12 weeks of drug washout, suggesting possible cellular metabolic treatment legacy effect [23]. Furthermore, Yaribeygi et al. suggested that GLP-1RAs can also improve insulin sensitivity, by proposing eight potential molecular pathways [24].

In PCOS and its common comorbidities, circulating levels of adipose-secreted zinc- α 2-glycoprotein (ZAG), an insulin-sensitizing cytokine, are considerably reduced [25][26]. A study on 82 PCOS women demonstrated that 12 weeks of twice a day exenatide 10 mcg or metformin 1000 mg significantly increased ZAG levels in both treatment arms compared to the baseline, without significant differences between the arms [22]. Further information on the metabolic effects was provided in a study evaluating the impact of exenatide on different metabolites in women with PCOS and matched controls [19]. The three-month trial demonstrated that triglycerides, HDL, LDL, total cholesterol, and branched-chain amino acid metabolism were improved following exenatide therapy [19].

Liraglutide administration in five patients with HAIR-AN syndrome, which represents an extreme case of PCOS with metabolic syndrome, resulted in a significant improvement in insulin resistance, adipose tissue amount, hyperandrogenemia, and the menstrual cycle regularity, despite minimal weight loss, therefore, the measured changes could be attributed to liraglutide action per se [27]. Additionally, a small study primarily investigated the liraglutide effect on liver fibrosis biomarkers in PCOS. Procollagen Type 3 amino-terminal peptide, which is a predictor of cirrhosis, was reduced after the intervention [28].

3. The Effects of GLP-1 Receptor Agonists on Menstrual Regularity in Polycystic Ovary Syndrome

Despite menstrual regularity being an important treatment outcome in PCOS, the effect of GLP-1 levels or treatment with GLP-1RAs remains insufficiently studied. The first study to investigate the impact of GLP-1RA on the menstrual cyclicity randomized 42 oligo-ovulatory and overweight PCOS women to exenatide, metformin, or both. After 24 weeks, a significant improvement in the ovulation rate was demonstrated in all the groups, with the highest rate in the combination group and the lowest in the metformin-only group. Furthermore, the improvement in menstrual regularity was significantly correlated with a reduction in body weight, suggesting weight loss to be the primary driving factor behind the reproductive improvement [12]. A similar correlation between the change in menstrual frequency and BMI was found in a 26-week randomized, placebo-controlled trial that explored the effect of liraglutide 1.8 mg daily on ovarian function in 72 women with PCOS [29]. The bleeding ratio of 0.87 or above (calculated by the number of menstrual bleedings divided by the number of months in the study period) was achieved in 62% of women in the liraglutide group compared with 28% in the placebo group [29]. However, several additional studies with liraglutide in PCOS found unaltered menstrual rate despite reductions in body weight [5][6][14] and insulin resistance [13]. Potential explanations might include small sample sizes, short duration, and the low liraglutide dose [30].

4. The Effects of GLP-1 Receptor Agonists on Pregnancy Rate in Polycystic Ovary Syndrome

There were two studies that addressed pregnancy rates in women with PCOS after an intervention with GLP-1RAs before conception, both reporting better pregnancy outcomes after the GLP-1RA withdrawal [16][17]. The first study included 176 overweight or obese women with PCOS and investigated the natural pregnancy rate in the following 12 weeks after a 12-week treatment with exenatide [17]. The study participants were randomized to receive either exenatide 10 mcg BID or metformin 1000 mg BID for the first 12 weeks, followed by metformin only for the second 12 weeks in which the natural pregnancy rate was tracked. In comparison to the metformin group, the participants receiving exenatide had significantly improved clinical variables after the first 12 weeks, including weight, total percentage of fat, HOMA-IR, and menstrual frequency. The study's main outcome, the natural pregnancy rate following pre-treatment, was significantly higher in the exenatide group compared to the metformin group (43.6% versus 18.70%, respectively). Although the study was not designed to investigate the underlying mechanisms of this difference in the reproductive outcome, the authors proposed weight loss to most likely be the main contributor to the improved fertility [17]. The second study included 28 obese women

with PCOS and explored intervention with low-dose liraglutide (1.2 mg QD) in combination with metformin. The combination of liraglutide and metformin was superior to metformin alone in increasing both the in vitro fertilization and cumulative (including spontaneous conception) pregnancy rates after pre-treatment in patients that were previously resistant to reproductive treatment. The pregnancy rate per embryo transfer was 85.7% in the combination group, compared to 28.6% in the metformin alone group. The cumulative pregnancy rate in 12 months was 69% in the combination compared to 36% in the metformin group. Those results could provide an additional perspective in understanding the direct reproductive effects of GLP-1RAs since both interventions resulted in comparable weight and visceral adipose tissue reductions, indicating other potential mechanisms of action beyond weight loss ^[16]. In addition, a case report of a 26-year-old infertile and obese PCOS woman reported successful pregnancy following 2-month preconception treatment with exenatide ^[31].

5. The Effects of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Polycystic Ovary Syndrome

PCOS is known to be linked to adverse cardiovascular risk since insulin resistance is a vital factor in its pathogenesis, importantly leading to several cardiometabolic abnormalities ^[32]. In comparison to age and BMI-matched healthy controls, women with PCOS have a 30% increased risk of cardiovascular disease ^[33]. Whether PCOS is associated with subclinical and clinical atherosclerosis, independent of risk factors that commonly accompany the disorder, is unclear ^[32]. In recent years, cardiovascular outcomes trials have demonstrated that GLP-1RAs can significantly reduce cardiovascular events in individuals with Type 2 diabetes mellitus, however, the majority of available studies with GLP-1RAs in PCOS did not study cardiometabolic endpoints ^{[34][35]}.

The first study that was designed to assess cardiometabolic endpoints was a 6-month controlled trial, which published its results in 2015. The effect of daily liraglutide 1.8 mg on weight loss and atherothrombosis markers was evaluated in a small group of PCOS women with obesity and controls. Liraglutide treatment was associated with a significant reduction in atherothrombosis markers in both groups, including inflammation, endothelial dysfunction, and clotting ^[13]. Two years later, the LIPT study (Liraglutide in PCOS on Markers of Vascular Thrombosis) reported effects of the same liraglutide dose in a 26-week study in 72 overweight PCOS women on markers of thromboembolism and cardiovascular disease. The trial demonstrated significant decreases in peak thrombin concentration and increases in time to start of thrombin generation and time to peak thrombin concentration. In addition, there was an improvement in fibrinolytic activity ^[36]. Additional cardiovascular biomarkers were reported by this research team in this study group a year later. Liraglutide treatment reduced the levels of the cardiovascular risk biomarkers for subclinical cardiovascular disease, midregional-pro-adrenomedullin by 25%, and midregional-pro-atrial natriuretic peptide by 6% (borderline significance) compared with placebo, whereas copeptin levels did not change ^[37]. The LIPT study also demonstrated reductions in liver fat content, visceral adipose tissue, and the prevalence of non-alcoholic fatty liver disease ^[8]. Furthermore, in a 4-month study that assessed the effect 16 weeks exenatide intervention on inflammation, endothelial dysfunction, and fibrinolytic activity in 30 overweight/obese women with PCOS, the treatment showed a significant reduction in the cardiovascular risk markers including cellular adhesion molecule 1, p-selectin as well as e-selectin, and an improvement in the C-reactive protein (CRP) ^[18].

References

1. Nuffer, W.A.; Trujillo, J.M. Liraglutide: A New Option for the Treatment of Obesity. *Pharmacotherapy* 2015, 35, 926–934.
2. Lewis, A.L.; McEntee, N.; Holland, J.; Patel, A. Development and approval of rybelsus (oral semaglutide): Ushering in a new era in peptide delivery. *Drug. Deliv. Transl. Res.* 2022, 12, 1–6.
3. Cena, H.; Chiovato, L.; Nappi, R.E. Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. *J. Clin. Endocrinol. Metab.* 2020, 105, e2695–e2709.
4. Wang, F.F.; Wu, Y.; Zhu, Y.H.; Ding, T.; Batterham, R.L.; Qu, F.; Hardiman, P.J. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: A systematic review and network meta-analysis. *Obes. Rev. Off. J. Int. Assoc. Study Obes.* 2018, 19, 1424–1445.
5. Jensterle Sever, M.; Kocjan, T.; Pfeifer, M.; Kravos, N.A.; Janez, A. Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin. *Eur. J. Endocrinol.* 2014, 170, 451–459.
6. Jensterle, M.; Kravos, N.A.; Pfeifer, M.; Kocjan, T.; Janez, A. A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed

polycystic ovary syndrome. *Hormones* 2015, 14, 81–90.

7. Rasmussen, C.B.; Lindenberg, S. The effect of liraglutide on weight loss in women with polycystic ovary syndrome: An observational study. *Front. Endocrinol.* 2014, 5, 140. Available online: <https://pubmed.ncbi.nlm.nih.gov/25221543> (accessed on 1 May 2022).
8. Frøssing, S.; Nylander, M.; Chabanova, E.; Frystyk, J.; Holst, J.J.; Kistorp, C.; Skouby, S.O.; Faber, J. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. *Diabetes Obes. Metab.* 2018, 20, 215–218.
9. Jensterle, M.; Gorcar, K.; Janez, A. Metformin as an initial adjunct to low-dose liraglutide enhances the weight-decreasing potential of liraglutide in obese polycystic ovary syndrome: Randomized control study. *Exp. Ther. Med.* 2016, 11, 1194–1200.
10. Srinivasan, D.; Lofton, H.F. Effect of GLP-1 agonists on weight loss in patients with polycystic ovary syndrome and obesity: A single-center study. *Obes. Pillars* 2022, 2, 100016. Available online: <https://www.sciencedirect.com/science/article/pii/S2667368122000079> (accessed on 1 May 2022).
11. Ma, R.L.; Deng, Y.; Wang, Y.F.; Zhu, S.Y.; Ding, X.S.; Sun, A.J. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. *Chin. Med. J.* 2021, 134, 2882–2889.
12. Elkind-Hirsch, K.; Marrioneaux, O.; Bhushan, M.; Vernor, D.; Bhushan, R. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. *J. Clin. Endocrinol. Metab.* 2008, 93, 2670–2678.
13. Kahal, H.; Aburima, A.; Ungvari, T.; Rigby, A.S.; Coady, A.M.; Vince, R.V.; Ajjan, R.A.; Kilpatrick, E.S.; Naseem, K.M.; Atkin, S.L. The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. *BMC Endocr. Disord.* 2015, 15, 14.
14. Jensterle, M.; Salamun, V.; Kocjan, T.; Vrtacnik Bokal, E.; Janez, A. Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: A pilot randomized study. *J. Ovarian. Res.* 2015, 8, 32.
15. Jensterle, M.; Kravos, N.A.; Goričar, K.; Janez, A. Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: Randomized trial. *BMC Endocr. Disord.* 2017, 17, 5.
16. Salamun, V.; Jensterle, M.; Janez, A.; Vrtacnik Bokal, E. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: A pilot randomized study. *Eur. J. Endocrinol.* 2018, 179, 1–11.
17. Liu, X.; Zhang, Y.; Zheng, S.Y.; Lin, R.; Xie, Y.J.; Chen, H.; Zheng, Y.; Liu, E.; Chen, L.; Yan, J.; et al. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome. *Clin. Endocrinol.* 2017, 87, 767–774.
18. Dawson, A.J.; Sathyapalan, T.; Vince, R.; Coady, A.M.; Ajjan, R.A.; Kilpatrick, E.S.; Atkin, S.L. The Effect of Exenatide on Cardiovascular Risk Markers in Women with Polycystic Ovary Syndrome. *Front. Endocrinol.* 2019, 10, 189. Available online: <https://pubmed.ncbi.nlm.nih.gov/31001199> (accessed on 1 May 2022).
19. Tang, L.; Yuan, L.; Yang, G.; Wang, F.; Fu, M.; Chen, M.; Liu, D. Changes in whole metabolites after exenatide treatment in overweight/obese polycystic ovary syndrome patients. *Clin. Endocrinol. (Oxf.)* 2019, 91, 508–516.
20. Elkind-Hirsch, K.E.; Chappell, N.; Seidemann, E.; Storment, J.; Bellanger, D. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. *J. Clin. Endocrinol. Metab.* 2021, 106, 3019–3033.
21. Jensterle Sever, M.; Ferjan, S.; Vovk, A.; Battelino, T.; Rizzo, M.; Janez, A. Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study. *Diabetes Res. Clin. Pract.* 2021, 2, 178.
22. Zheng, S.; Liu, E.; Zhang, Y.; Long, T.; Liu, X.; Gong, Y.; Mai, T.; Shen, H.; Chen, H.; Lin, R.; et al. Circulating zinc- α 2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment. *Endocr. J.* 2019, 66, 555–562.
23. Frías, J.P.; Guja, C.; Hardy, E.; Ahmed, A.; Dong, F.; Öhman, P.; Jabbour, S.J. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): A 28 week, multicentre, double-blind, phase 3, randomised control. *Lancet Diabetes Endocrinol.* 2016, 4, 1004–1016.
24. Yarıbeygi, H.; Sathyapalan, T.; Sahebkar, A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. *Life Sci.* 2019, 234, 116776.

25. Yang, M.; Liu, R.; Li, S.; Luo, Y.; Zhang, Y.; Zhang, L.; Liu, D.; Wang, Y.; Xiong, Z.; Boden, G.; et al. Zinc- α 2-glycoprotein is associated with insulin resistance in humans and is regulated by hyperglycemia, hyperinsulinemia, or liraglutide administration: Cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes. *Diabetes Care* 2013, 36, 1074–1082.
26. Lai, Y.; Chen, J.; Li, L.; Yin, J.; He, J.; Yang, M.; Yang, M.; Jia, Y.; Liu, D.; Liu, H.; et al. Circulating Zinc- α 2-glycoprotein levels and Insulin Resistance in Polycystic Ovary Syndrome. *Sci. Rep.* 2016, 6, 25934. Available online: <https://doi.org/10.1038/srep25934> (accessed on 1 May 2022).
27. Livadas, S.; Androulakis, I.; Angelopoulos, N.; Lytras, A.; Papagiannopoulos, F.; Kassi, G. Liraglutide administration improves hormonal/metabolic profile and reproductive features in women with HAIR-AN syndrome. *Endocrinol. Diabetes Metab. Case Rep.* 2020, 2020, 19–150. Available online: <https://pubmed.ncbi.nlm.nih.gov/32554829> (accessed on 1 May 2022).
28. Kahal, H.; Abouda, G.; Rigby, A.S.; Coady, A.M.; Kilpatrick, E.S.; Atkin, S.L. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease. *Clin. Endocrinol.* 2014, 81, 523–528.
29. Nylander, M.; Frøssing, S.; Clausen, H.V.; Kistorp, C.; Faber, J.; Skouby, S.O. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: A randomized clinical trial. *Reprod. Biomed. Online* 2017, 35, 121–127.
30. Jensterle, M.; Janez, A.; Fliers, E.; DeVries, J.H.; Vrtacnik-Bokal, E.; Siegelaar, S.E. The role of glucagon-like peptide-1 in reproduction: From physiology to therapeutic perspective. *Hum. Reprod. Update* 2019, 25, 504–517.
31. Yang, Q.; Wang, F. Successful Pregnancy after Improving Insulin Resistance with the Glucagon-Like Peptide-1 Analogue in a Woman with Polycystic Ovary Syndrome: A Case Report and Review of the Literature. *Gynecol. Obstet. Investig.* 2016, 81, 477–480.
32. Osibogun, O.; Ogunmoroti, O.; Michos, E.D. Polycystic ovary syndrome and cardiometabolic risk: Opportunities for cardiovascular disease prevention. *Trends Cardiovasc. Med.* 2020, 30, 399–404.
33. Zhao, L.; Zhu, Z.; Lou, H.; Zhu, G.; Huang, W.; Zhang, S.; Liu, F. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): A meta-analysis. *Oncotarget* 2016, 7, 33715–33721.
34. Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jodar, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; et al. Warren. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N. Engl. J. Med.* 2016, 375, 1834–1844.
35. Marso, S.P.; Daniels, G.H.; Frandsen, K.B.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N. Engl. J. Med.* 2016, 375, 311–322.
36. Nylander, M.; Frøssing, S.; Kistorp, C.; Faber, J.; Skouby, S.O. Liraglutide in polycystic ovary syndrome: A randomized trial, investigating effects on thrombogenic potential. *Endocr. Connect.* 2017, 6, 89–99.
37. Frøssing, S.; Nylander, M.; Kistorp, C.; Skouby, S.O.; Faber, J. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. *Endocr. Connect.* 2018, 7, 115–123. Available online: <https://pubmed.ncbi.nlm.nih.gov/29295870> (accessed on 1 May 2022).